Scripps Research Institute

Scientists find 3D structure of key drug target for diabetes

Wednesday, July 24, 2013 09:24 AM

An international team led by scientists at The Scripps Research Institute (TSRI), an independent, nonprofit organization focused on research in the biomedical sciences, has determined and analyzed the three-dimensional atomic structure of the human glucagon receptor. The receptor, found mainly on liver and kidney cells, helps regulate glucose levels in the bloodstream and is the target of potential therapeutic agents for type 2 diabetes.

More... »

Scripps Research, Takeda expand research collaboration

Wednesday, March 20, 2013 09:11 AM

The Scripps Research Institute (TSRI), an independent, not-for-profit organization focusing on research in the biomedical sciences, and Takeda Pharmaceutical, a research-based global pharmaceutical company, plan to expand their recent research collaboration to search for new drug targets for a variety of diseases.

More... »

RQx Pharmaceuticals, collaborate on novel drug compounds

Wednesday, February 13, 2013 11:29 AM

RQx Pharmaceuticals, a biopharmaceutical company developing broad-spectrum small molecule antibiotics for serious life-threatening infections, has entered into a drug discovery collaboration with Genentech, a member of the Roche Group, for the discovery and development of novel drug compounds for an undisclosed target.

More... »

Epic Sciences completes $13M Series B financing to advance cancer diagnostics

Wednesday, November 14, 2012 12:01 PM

Epic Sciences, a La Jolla, Calif.-based private biotech company that develops breakthrough cancer diagnostics, completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture Fund and Pfizer Venture Investments, in addition to undisclosed individual investors.

More... »

Proteostasis, Scripps Research expand collaboration on cystic fibrosis

Friday, July 27, 2012 12:04 PM

Proteostasis Therapeutics, a therapeutics developer focusing on regulating protein homeostasis for neurodegenerative and orphan diseases, has expanded its collaboration with The Scripps Research Institute (TSRI) to encompass an additional funded research project focused on biology and the testing of small molecule modulators of protein folding and trafficking for the treatment of cystic fibrosis (CF).

More... »

Scripps Research inks 5-year research collaboration with BMS

Friday, June 15, 2012 03:37 PM

The Scripps Research Institute, an independent, not-for-profit organization focused on research in the biomedical sciences, has entered into a five-year collaboration with Bristol-Myers Squibb (BMS) focusing on applying novel chemistry to drug discovery and synthesis.

More... »

Repligen enrolls first patient in phase I trial of Friedreich’s Ataxia

Monday, March 19, 2012 03:20 PM

Waltham, Mass.-based Repligen has enrolled the first patient in a phase I clinical trial of RG2833 in adult patients with Friedreich’s Ataxia (FA)—a debilitating, life-shortening, degenerative neuro-muscular disorder that currently has no treatment.

More... »

LEO Pharma and Scripps Research Institute collaborate

Tuesday, July 19, 2011 01:39 PM

LEO Pharma and The Scripps Research Institute have entered a research collaboration.

More... »